Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05052528 |
|
Recruitment Status :
Recruiting
First Posted : September 22, 2021
Last Update Posted : March 10, 2022
|
Sponsor:
Mehrdad Abedi, MD
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Mehrdad Abedi, MD, University of California, Davis
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 15, 2024 |
| Estimated Study Completion Date : | February 15, 2025 |